Cost-effectiveness in the prevention of colorectal cancer

Gastroenterology Clinics of North America

Volumn 31, Issue 4, 2002, Pages 1069-1091

  Sonnenberg, Amnon ^a,b  

^a VA Medical Center   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL DISEASE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; OCCULT BLOOD TEST; PATIENT COMPLIANCE; QUALITY ADJUSTED LIFE YEAR; REVIEW; SCREENING TEST; SIGMOIDOSCOPY;

COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; MASS SCREENING; MODELS, ECONOMIC; SENSITIVITY AND SPECIFICITY;

EID: 0036894265     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8553(02)00051-1     Document Type: Review

References (54)

1. Siegel JE, Weinstein MC, Torrance GW. Reporting cost-effectiveness studies and results. In: Gold MR, Siegel JE, Russel LB, Weinstein MC, editors. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996. p. 276-303.
2. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Ed 2. Cost-Effectiveness Analysis (chapter 5). New York: Oxford University Press; 1997. p. 96-138.
3. Delcò F, Sonnenberg A. Limitations of the fecal occult blood test in screening for colorectal cancer. Ital J Gastroenterol Hepatol 1999;31:119-26.
4. Wallace MB, Kemp JA, Trnka YM, Donovan JM, Farraye FA. Is colonoscopy indicated for small adenomas found by screening flexible sigmoidoscopy? Ann Intern Med 1998;129:273-8.
5. Ahlquist DA, Moertel CG, McGill DB. Screening for colorectal cancer. [letter] N Eng] J Med 1993;329:1351-4.
6. Allison JE, Tekawa IS, Ranson LJ, Adrian AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-9.
7. Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards BK, editors. SEER Cancer Statistics Review, 1973-1994. Bethesda, MD: National Cancer Institute; 1997. NIH Publication No. 97-2789.
8. Ransohoff DF. Colorectal cancer. In: Everhart JE, editor. Digestive Diseases in the United States: Epidemiology and Impact. US Department of Health and Human Services. Washington, DC: US Government Printing Office; 1994. NIH publication No. 94-1447: 205-223.
9. Weinstein MC, Fineberg HV, Elstein AS, Frazier HS, Neuhauser D, Neutra RR, et al., editors. Clinical Decision Analysis. Philadelphia: WB Saunders Company; 1980. p. 92-113.
10. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993;328:1365-71.
11. Selby JV, Friedman GD, Quesenberry CP, Weiss NS. Effect of fecal occult blood testing on mortality from colorectal cancer. Ann Intern Med 1993;118:1-6.
12. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71.
13. Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
14. Lindholm E, Berglund B, Haglind E, Kewenter J. Factors associated with participation in screening for colorectal cancer with fecal occult blood testing. Scand J Gastroenterol 1995;30:171-6.
15. Towler B, Irwing L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test. Hemoccult. Br Med J 1998;317:559-66.
16. Eddy DM. Screening for colorectal cancer. Ann Intern Med 1990;113:373-84.
17. Wagner JL, Herdman RC, Wadhwa S. Cost-effectiveness of colorectal cancer screening in the elderly. Ann Intern Med 1991;115:807-17.
18. Lieberman DA. Cost-effectiveness model for colon cancer screening. Gastroenterology 1995;109:1781-90.
19. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000;284:1954-61.
20. Ransohoff DF, Sandler RS. Screening for colorectal cancer. N Engl J Med 2002;346:40-4.
21. Sonnenberg A, Delcò F, Inadomi JM. The cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000;133:573-84.
22. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
23. Rex DK, Johnson DA, Lieberman DA, Burt RW, Sonnenberg A. Colorectal cancer prevention 2000: Screening recommendations of the American College of Gastroenterology. Am J Gastroenterol 2000;94:868-77.
24. Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C. Runowicz, et al. American Cancer Society guidelines for the early dectection of cancer. CA Cancer J Clin 2002;52:8-22.
25. Ness RM, Holmes AM, Klein R, Dittus R. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol 2000;95:1800-11.
26. Ransohoff DF, Lang CA. Cost-effectiveness of one-time colonoscopy screening to reduce colorectal cancer mortality. Gastroenterology 1994;106:A24.
27. Delcò F, Sonnenberg A. At what age should a one-time only colonoscopy for screening of colorectal cancer be performed? Eur J Gastroenterol Hepatol 1999;11:1319-20.
28. Murray CJL. Quantifying the burden of disease: The technical basis for disability-adjusted life years. Bull World Health Organ 1994;72:429-45.
29. Selby JV, Friedman GD, Quesenberry CP, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992;326:653-7.
30. Müller A, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. Ann Intern Med 1995;123:904-10.
31. Müller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer: A case-control study among veterans. Arch Intern Med 1995;155:1741-8.
32. Sonnenberg A, Delcò F. Cost-effectiveness of a single colonoscopy in screening for colorectal cancer. Arch Int Med 2002;162:163-8.
33. Shinya Y, Wolff WI. Morphology, anatomic distribution and cancer potential of colonic polyps. Ann Surg 1979;190:679-83.
34. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. N Engl J Med 2000;343:162-8.
35. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000;343:169-74.
36. Hara AK, Johnson CD, Reed JE, Ahlquist DA, Nelson H, MacCarty RL, et al. Detection of colorectal polyps with CT colography: Initial assessment of sensitivity and specificity. Radiology 1997;205:59-65.
37. Schoenenberger AW, Bauerfeind P, Krestin GP, Debatin JF. Virtual colonoscopy with magnetic resonance imaging: In vitro evaluation of a new concept. Gastroenterology 1997;112:1863-70.
38. Royster AP, Fenlon HM, Clarke PD, Nunes DP, Ferrucci JT. CT colonoscopy of colorectal neoplasms: Two-dimensional and three-dimensional virtual-reality techniques with colonoscopic correlation. Am J Roentgenol 1997;169:1237-42.
39. Pauker SG, Kassirer JP. The threshold approach to clinical decision making. N Engl J Med 1980;302:1109-17.
40. Sonnenberg A, Delcò F, Bauerfeind P. Is virtual colonoscopy a cost-effective option to screen for colorectal cancer? Am J Gastroenterol 1999;94:2268-74.
41. Thun MJ, Namboodiri MM, Heath Jr. CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
42. Müller AD, Sonnenberg A, Wasserman IH. Diseases preceding colon cancer: A casecontrol study among veterans. Dig Dis Sci 1994;39:2480-4.
43. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
44. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
45. Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick ME. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 2001;135:769-81.
46. Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: A cost-effectiveness analysis. Gastroenterology 2002;122:78-84.
47. Smalley WE, Griffin MR, Fought RL, Ray WA. Excess cost from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996;11:461-9.
48. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999;117:776-83.
49. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
50. Eddy DM. Screening for Cancer: Theory, Analysis, and Design. Englewood Cliffs, NJ: Prentice-Hall; 1980. p. 79-95.
51. Morrison AS. Screening in Chronic Disease. Ed 2. Oxford, UK: Oxford University Press; 1992. p. 60-66.
52. Koretz RL. Is routine screening for colorectal cancer justifiable? Postgrad Med 1997;102:49-62.
53. Koretz RL. Surveying the masses. [comment] Gastroenterology 2000;119:1403-5.
54. Hoff G, Thiis-Evensen E, Grotmol T, Sauar J, Vatn MH, Moen IE. Do undesirable effects of screening affect all-cause mortality in flexible sigmoidoscopy programmes? Experience from the Telemark Polyp Study 1983-1996. Eur J Cancer Prev 2001;10:131-7.